ARKG vs IBB
ARK Genomic Revolution ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.75% for ARKG.
- • IBB pays a higher dividend yield (0.22%).
Side-by-side metrics
| Metric | ARKG | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.75% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $1.73B | $9.09B |
YTD return | 44.53% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 2.38 | 0.69 |
P/E ratio | — | 24.89 |
Last price | $43.00 | $197.34 |
Inception | — | — |
Issuer | ARK | iShares |
ARKG top holdings
| TWST | Twist Bioscience Corp | 9.15% |
| TEM | Tempus AI Inc Class A common stock | 7.64% |
| ABSI | Absci Corp | 7.01% |
| TXG | 10x Genomics Inc Ordinary Shares - Class A | 7.00% |
| CRSP | CRISPR Therapeutics AG | 6.56% |
| PSNL | Personalis Inc | 6.19% |
| BEAM | Beam Therapeutics Inc | 4.34% |
| GH | Guardant Health Inc | 4.28% |
| NTRA | Natera Inc | 4.11% |
| ILMN | Illumina Inc | 3.98% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About ARKG
ARKG (ARK Genomic Revolution ETF) is Companies advancing genomics and molecular biology. Managed by ARK, the fund carries $1.7B in assets under management, an expense ratio of 0.75%. Its largest holding is Twist Bioscience Corp (TWST), which represents 9.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.